NCT03835819View on ClinicalTrials.gov

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 2, 2020

Primary Completion Date

June 4, 2024

Study Completion Date

May 1, 2027

Conditions
Endometrial Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells

DRUG

IMGN853

Mirvetuximab soravtansine is an antibody-drug conjugate.

Trial Locations (3)

11042

Northwell Cancer Institute, Lake Success

02215

Dana Farber Cancer Institute, Boston

01605

University of Massachusetts, Worcester

Sponsors

Collaborators (1)

ImmunoGen, Inc.
All Listed Sponsors
collaborator

ImmunoGen, Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03835819 - A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) | Biotech Hunter | Biotech Hunter